What is an autologous stem cell transplant?
An autologous stem cell transplant (often called an auto transplant or ASCT) is a treatment that allows doctors to give very high doses of chemotherapy, sometimes with radiotherapy, and then rescue the bone marrow using the patient’s own stem cells. “Autologous” means “from yourself”.
The bone marrow contains blood stem cells, which make all red cells, white cells and platelets. High-dose chemotherapy can kill cancer cells more effectively than standard doses, but it also destroys the bone marrow. By collecting and freezing your own stem cells beforehand, and giving them back after the chemotherapy, the marrow can recover in a few weeks.
Strictly speaking, the stem cells themselves do not treat the cancer. The high-dose chemotherapy is the treatment, and the stem cells act as a rescue. This is different from an allogeneic transplant, in which stem cells come from a donor and the donor’s immune cells also attack the cancer.
Autologous versus allogeneic transplant
| Feature | Autologous transplant | Allogeneic transplant |
|---|---|---|
| Source of stem cells | Your own | A matched donor |
| Donor needed | No | Yes |
| Graft-versus-host disease | Does not occur | A major risk |
| Immune attack on cancer from graft | No | Yes (graft-versus-tumour effect) |
| Risk of treatment-related death | Lower | Higher |
| Main uses | Myeloma, lymphoma, some solid tumours | Leukaemias, myelodysplastic syndromes, some lymphomas |
A brief history
The first successful bone marrow transplants were carried out in the 1950s and 1960s. Early autologous transplants used marrow collected from the hip bones under anaesthetic. Today, almost all autologous transplants use stem cells collected from the blood, which is simpler for the patient and leads to faster recovery of blood counts. A review of stem cell transplantation describes this shift towards blood-derived stem cells and the growth of transplant as a treatment for many blood cancers (Copelan, 2006).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | High-dose chemotherapy with stem cell rescue |
| Main uses | Multiple myeloma, relapsed lymphoma, some solid tumours in children and young adults |
| Stem cell source | Usually your own blood, collected after growth factor injections |
| Common high-dose drugs | Melphalan for myeloma; BEAM or similar combinations for lymphoma |
| Hospital stay | Usually 2-4 weeks; some centres offer outpatient care |
| Recovery | Blood counts recover in 2-3 weeks; full recovery takes several months |
| Main risks | Infection, mouth sores, diarrhoea, tiredness, rarely organ damage |
2. How it works
| Stage | Purpose |
|---|---|
| Induction treatment | Standard treatment to shrink the cancer first |
| Stem cell mobilisation | Growth factor injections, sometimes with chemotherapy or plerixafor, push stem cells out of the marrow into the blood |
| Collection (apheresis) | Stem cells are filtered from the blood and frozen |
| Conditioning | High-dose chemotherapy kills remaining cancer cells and wipes out the marrow |
| Stem cell infusion | Thawed stem cells are given back through a drip |
| Engraftment | Stem cells travel to the marrow and start making new blood cells |
A review of conditioning describes how the early idea was simple: give the highest tolerable dose to eliminate the disease, then restore blood production with the graft (Gyurkocza and Sandmaier, 2014). For autologous transplants this principle still applies.
3. Who it is for
Conditions treated
| Condition | Role of autologous transplant |
|---|---|
| Multiple myeloma | Standard part of first-line treatment for fit patients |
| Hodgkin lymphoma | Relapsed disease that still responds to chemotherapy |
| Diffuse large B-cell lymphoma | Relapsed disease; CAR-T is now often preferred for early relapse |
| Mantle cell lymphoma | Consolidation after first treatment in some fit patients |
| Primary central nervous system lymphoma | Consolidation with drugs that reach the brain |
| Peripheral T-cell lymphoma | Consolidation in first remission for some types |
| AL amyloidosis | Selected patients with good organ function |
| POEMS syndrome | Widespread disease in suitable patients |
| Neuroblastoma | High-risk disease in children |
| Testicular germ cell tumours | Relapsed disease, sometimes as tandem transplants |
Who may be suitable
| Factor | Typical consideration |
|---|---|
| Fitness | Good general health and organ function |
| Age | Biological fitness matters more than age; many people over 65 are treated |
| Disease response | The cancer usually needs to respond to prior chemotherapy |
| Stem cell collection | Enough stem cells must be collected |
| Support | Someone to help during recovery at home |
Why transplant is used in myeloma
Myeloma is a cancer of plasma cells in the bone marrow that is very sensitive to the drug melphalan. Giving melphalan at a high dose deepens the response achieved by first-line drugs. In the IFM 2009 trial, more people who had a transplant reached a complete response and had no detectable remaining disease on sensitive tests (Attal et al., 2017).
Tandem transplants
In some situations, two autologous transplants are given a few months apart. This is called a tandem transplant. It is used in selected people with high-risk myeloma, in high-risk neuroblastoma in children and in relapsed germ cell tumours. Enough stem cells must be collected at the start for both procedures.
4. Before treatment
| Step | Details |
|---|---|
| Work-up | Heart scan, lung function, kidney and liver tests, infection screening |
| Dental check | Treat any problems before high-dose chemotherapy |
| Central line | A tunnelled line or PICC is placed |
| Fertility preservation | Sperm or egg storage if appropriate |
| Mobilisation | Daily G-CSF injections for 4-5 days, sometimes after a dose of chemotherapy |
| Apheresis | Usually 1-3 days of collection, 3-5 hours each |
| Cell freezing | Cells are frozen until needed |
5. What to expect: step by step
| Step | Timing | What happens |
|---|---|---|
| 1. Admission | Day -2 to -7 | Admitted to a transplant unit, often in a single room |
| 2. High-dose chemotherapy | Days -7 to -1 | One or several days, depending on the regimen |
| 3. Stem cell infusion | Day 0 | Cells are thawed and given through a drip over minutes to an hour; it feels like a blood transfusion |
| 4. Low-count period | Days 3-12 | Blood counts fall to very low levels; risk of infection, bleeding and mouth sores |
| 5. Supportive care | Throughout | Antibiotics, transfusions, pain relief, nutrition support |
| 6. Engraftment | Days 10-15 | White cells start to rise |
| 7. Discharge | Usually days 14-21 | Once counts recover and you can eat and drink |
| 8. Early follow-up | Weeks 3-12 | Frequent clinic visits and blood tests |
The day of infusion
Many people call the infusion day their “new birthday”. The stem cells are kept in a preservative that can cause a strong taste of sweetcorn or garlic, a tickly cough or nausea for a few hours. You may notice the smell on your breath for a day or two.
6. Side effects and risks
| Side effect | When it occurs | Notes |
|---|---|---|
| Infection | Mostly during low counts | Fever needs urgent antibiotics |
| Mouth sores (mucositis) | Days 3-14 | Can make eating painful; strong pain relief may be needed |
| Nausea, vomiting and diarrhoea | First 2 weeks | Anti-sickness medicines and fluids |
| Hair loss | Weeks 2-3 | Regrows over a few months |
| Tiredness | Weeks to months | The most persistent effect |
| Bleeding | Low platelets | Platelet transfusions |
| Engraftment syndrome | Around engraftment | Fever, rash, fluid retention; usually settles with steroids |
| Organ damage | Uncommon | Heart, lung, liver or kidney |
| Infertility | Often | High-dose chemotherapy commonly affects fertility |
| Second cancers | Rare, years later | Including blood cancers |
| Treatment-related death | Low, usually 1-2% or less | Higher in people with other illnesses |
7. Results and outlook
| Study | Main finding |
|---|---|
| IFM 2009, newly diagnosed myeloma (700 adults) | Transplant after RVD induction lengthened median progression-free survival from 36 to 50 months, though overall survival at four years was similar (Attal et al., 2017) |
| PARMA, relapsed chemotherapy-sensitive lymphoma (109 randomised) | Five-year event-free survival was 46% with transplant versus 12% with standard chemotherapy, and overall survival 53% versus 32% (Philip et al., 1995) |
The PARMA trial established autologous transplant as a standard for relapsed aggressive lymphoma that still responds to chemotherapy. In myeloma, transplant remains a standard option for fit patients, although newer drug combinations continue to change the picture.
8. Recovery and aftercare
Recovery timeline
| Period | What to expect |
|---|---|
| Weeks 1-4 after discharge | Tiredness, low appetite; frequent clinic visits |
| Months 1-3 | Energy slowly returns; avoid crowds and infections |
| Months 3-6 | Many people return to work or study, often part time |
| Around 6-12 months | Repeat childhood vaccinations begin, as immunity from earlier vaccines is lost |
| Long term | Follow-up for disease control and late effects |
Protecting yourself from infection
- Wash hands often and ask visitors to do the same
- Avoid people with colds, flu or stomach bugs
- Follow food safety advice, such as avoiding undercooked meat and unpasteurised products
- Take preventive medicines such as antivirals as prescribed
- Call your team for a temperature of 38 C or higher
Maintenance treatment
In myeloma, lenalidomide maintenance is usually started a few months after transplant to keep the disease under control for longer. In the IFM 2009 trial, both groups received a year of lenalidomide maintenance (Attal et al., 2017).
Eating and drinking
Taste changes, mouth soreness and poor appetite are common for weeks. Small, frequent meals and high-calorie drinks can help you regain weight and strength. A dietitian at the transplant centre can give advice tailored to you.
Late effects to watch for
| Late effect | What can help |
|---|---|
| Persistent tiredness | Gradual exercise programmes |
| Early menopause or low testosterone | Hormone checks and replacement if needed |
| Thyroid problems | Regular blood tests, especially after radiotherapy |
| Cataracts | Eye checks, particularly after total body irradiation or steroids |
| Bone thinning | Bone density scans, calcium and vitamin D |
| Second cancers | Routine screening and reporting new symptoms |
Driving, travel and pets
Most people are advised not to drive for the first few weeks, while tiredness and medicines may affect concentration. Avoid long-haul travel and crowded places until your team agrees. Ask someone else to clean litter trays, bird cages and fish tanks for a few months, as these can carry infections.
Emotional recovery
The months after a transplant can bring mixed feelings: relief that the main treatment is over, along with worry about the cancer returning and frustration at slow progress. Support from transplant nurses, psychologists, peer groups and family is valuable. Many centres run survivorship clinics.
Returning to everyday life
Recovery is rarely a straight line. Good days are often followed by tired ones, and it can take six months to a year before energy feels close to normal. Setting small goals, such as a daily walk, and gradually increasing them helps rebuild fitness. Talk to your employer early about a phased return to work, and ask your team for a letter explaining what support you need.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Continued standard-dose drug treatment | Myeloma in people who are not fit for, or choose not to have, a transplant |
| CAR-T cell therapy | Early relapse or resistant large B-cell lymphoma, myeloma |
| Allogeneic stem cell transplant | When a donor graft-versus-tumour effect is needed |
| Bispecific antibodies | Relapsed lymphoma and myeloma |
| Radiotherapy | Localised disease |
| Clinical trials | New combinations |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is it an operation? | No; the stem cells are given through a drip |
| Will I need a donor? | No; your own stem cells are used |
| Can the cancer be in the collected cells? | A small number of cancer cells may be present, but this is rarely the main cause of relapse |
| How long will I be in hospital? | Usually 2-4 weeks |
| Will I lose my hair? | Usually yes, temporarily |
| When can I go back to work? | Often after 3-6 months |
| Can I have a second transplant? | Sometimes, if stem cells were stored and the disease returns after a long remission |
11. Questions to ask your care team
- What are the benefits of a transplant for my condition?
- Which high-dose regimen will I receive?
- How long will I be in hospital?
- How will my fertility be affected?
- What support will I need at home?
- When can I return to work and normal life?
- Will I need maintenance treatment afterwards?
Resources
- Attal, M. et al. (2017) ‘Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma’, New England Journal of Medicine, 376(14), pp. 1311-1320.
- Copelan, E.A. (2006) ‘Hematopoietic stem-cell transplantation’, New England Journal of Medicine, 354(17), pp. 1813-1826.
- Gyurkocza, B. and Sandmaier, B.M. (2014) ‘Conditioning regimens for hematopoietic cell transplantation: one size does not fit all’, Blood, 124(3), pp. 344-353.
- Philip, T. et al. (1995) ‘Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma’, New England Journal of Medicine, 333(23), pp. 1540-1545.
- National Cancer Institute (2026) Stem Cell and Bone Marrow Transplants for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant (Accessed: October 2026).
Prepared by the editorial team, October 2026.